Pharm for Movement Disorders Flashcards
What are some agents used to tx Parkinson’s disease?
L-Dopa (levodopa); L-DOPA/carbidopa (Sinemet)Dopamine receptor agonists: Bromocriptime, pramipexole, ropinirole, and apomorphineEnhancement of dopamine release: AmantadineAntimuscarinics: Benztropine, Diphenhydramine, and Trihexyphenidyl
What drugs that decrease dopamine metabolism can be used for Parkinson’s tx?
MAO-B: Selegiline, RasagilineCOMT: Entacapone, Tolcapine
What agents are used to tx Huntington Disease?
VMAT Inhibitors-DA depleting agents: Reserpine, tetrabenazineDopamine D2 receptor antagonistsLChlorpromazine, haloperidol
Parkinson disease
A progressive movement disorder affecting 1.5 million people in the U.S. with an average onset of 55 yrs (~10% of cases present before 40 yo)
Parkinson consists of what 4 primary clinical features?
Bradykinesia (slowness of movement)Muscular rigidity (increased muscle tone and resistance)resting tremor (abates during voluntary movement)Postural instability and impaired gait
What causes idiopathic PD?
unknown, although exposure to neurotoxins or generation of free radicals are thought to contribute
T or F. There is a genetic component of PD
T. AD forms of the disease lie in mutations of the gene encoduing a-synuclein (a synaptic protein), LRRK2 (leucine-rich repeat kinase 2), parkin (a ubiquitin hydrolase), and UCHL1 (also involved in ubiquitin mediated protein degradation)
PD has been associated with environmental factors such as:
infection with encephalitis, stroke, trauam, MPTP, and antipsychotic drug tx
The hallmark neurological feature of PD is:
selective loss of the pigmented (neuromelanin) neurons in the substantia nigra pars compactamost symptoms dont appear until striatal DA neuron levels decline by at least 70-80%
The basal ganglia consists of severl subcortical nuclei that participate in movement control. These nuclei are interconnected to form 2 pathways that form a feedbakc loop to the cortex. What are they?
direct pathway (cerebral cortex, striatal neurons (SNpc), SN para reticulata/edial globus pallidus, thalamus, cerebral cortex)indirect pathway (cerebral cortex, striatal neurons (SNpc), lateral globus pallidus, subthalmic nucleus, SN para reticulata/edial globus pallidus, thalamus, cerebral cortex)
What is the net effect of thedirect pathway? Indirect?
Direct: increased thalamic outputIndirect: less thalamic output
Describe the direct pathway of striatal control
the substantia nigra pars compacta synapses with the striatum via excitatory D1 receptors to project to the direct pathway while inhibiting the indirect pathway neurons in the striatum via D2 receptor binding (thus, under normal conditions the SN pars compacts favors the direct pathway)However in PD, activity of the indirect pathway predominatesD2 receptor activation appears to be the most important in gating the balance of the two pathways
Describe the metabolism of dopamine
1) tyrosine is converted to dopa via tyrosine hydroxylase2) dopa is converted to dopamine via who fucking cares (aka aromatic-L-amino acid decarboxylase)Dopamine is then packaged into vesicles that merge with the presynaptic membrane or broken down to DOPAC via MAO
What happens to dopamine in a synaptic cleft?
binds to postsynaptic membrane orconverted to 3MT via COMT and then to HVA via MAO
T or F. DA cannot cross the BBB into the CNS
T.
______, the immediate precursor to DA, is the single msot effective tx of PD
L-DOPA (levodopa)
How does L-DOPA work?
it replenishes DA stores in the remaining DA terminals in the striatum
Describe the pharmacokinetics of LevoDOPA
L-DOPA is readily absorbed from the GI tract (dependent on gastric emptying), plasma concentrations peak fast (1-2hrs) and the t1/2 is brief (1-3 hrs)It is heavily (99%) converted in the periphery and brain to DA by L-aromatic amino acid decarboxylase (L-AAD) and then principally excreted in the urine as HVA and DOPAC
T or F. L-DOPA must be given in high doses when used alone
T. Therefore, it is often coadministered with carbidopa, a L-AAD inhibitor that cant cross the BBB, thus prolonging the half-life of L-DOPA, reducing the amount of L-DIOA needed to be given by up to 75% and reducing side effects due to reduced levels of peripheral DA
What are the major AEs of L-DOPA monotherapy?
GI (anorexia, N/V)- tends to decrease with repeated useCV (arrhythmias, tachycardia, ventricular extrasystoles, a. fib)- incidence tends to be low except in those predisposed. Orthostatis hypotension common
What are the major AEs of L-DOPA/carbidopa therapy?
Behavioral (depression, anxiety, delusion, agitation, etc.) Use antipsychoticsDyskinesias (chorea, myoclonus, tics, tremor (intentional))